• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Ribociclib in addition to letrozole increases overall survival compared to letrozole alone

byKassandra McFarlaneandSamuel Chan
March 21, 2022
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Overall survival was longer in the group receiving ribociclib with letrozole as compared with the placebo group

2. Severe adverse events, especially neutropenia, are more prevalent in the ribociclib group compared to the placebo group

Evidence Rating Level: 1 (Excellent)

Study Rundown: This study aimed to compare the overall survival (OS) of postmenopausal women with hormone receptor (HR)-positive, HER2-negative recurrent or metastatic breast cancer receiving either ribociclib-letrozole or placebo-letrozole combinations. Additionally, the safety profile of ribociclib-letrozole was reported. The OS was longer in the group receiving ribociclib with letrozole as compared with the placebo group (63.9 months vs. 51.4 months, respectively). As well, Kaplan-Meier survival curves showed greater OS at 48, 60, and 72 months for the ribociclib group as compared to the placebo group (60.9% vs. 55.2%, 52.3% vs. 43.9%, 44.2% vs. 32.0%, respectively). The most common severe adverse effect (AE) was neutropenia and more patients taking ribociclib experienced this than those on placebo. Other less common, but severe AEs, included hepatobiliary toxic effects and prolonged QT interval, both of which were more prevalent in the ribociclib group. However, there were no new safety signals reported during this study. Limitations to this study include the under-representation of Black patients (2.5% of the trial participants) as the majority of patients recruited were from Europe and North America. As such, the results from this study must be interpreted with that in mind. Overall, the addition of ribociclib to letrozole increased the overall survival of postmenopausal female patients with HR-positive, HER2-negative recurrent or metastatic breast cancer as compared to placebo with letrozole.

Click to read the study in The New England Journal of Medicine

Relevant Reading: Treating cancer with selective CDK4/6 inhibitors

In-Depth [randomized controlled trial]: This phase 3 randomized controlled trial randomly assigned 668 postmenopausal female patients with HR-positive, HER2-negative recurrent or metastatic breast cancer on a 1:1 basis to receive either ribociclib with letrozole or placebo with letrozole. Patients who had previously received CDK4/6 inhibitors or previous systemic endocrine or chemo-therapy were ineligible. Group allocation was blinded to all involved. The median overall survival was greater in the ribociclib-letrozole group at 63.9 months, compared to the placebo-letrozole group at 51.4 months (hazard ratio (HR), 0.76; 95% confidence interval (CI), 0.63 to 0.93). The estimate of OS by Kaplan-Meier curves at 60 months was less in the placebo group at 43.9% (95% CI, 38.3% to 49.4%) compared to the ribociclib group at 52.3% (95% CI, 46.5% to 57.7%). At 72 months, the Kaplan-Meier curves showed OS at 44.2% for the ribociclib group (95% CI, 38.5% to 49.8%) compared to 32.0% for the placebo group (95% CI, 26.8% to 37.3%). Neutropenia was the most common severe AE and patients on ribociclib were affected more so than those on placebo (63.8% vs. 1.2%). Other severe AEs that were more common in the ribociclib group include hepatobiliary toxic effects (14.4% vs. 4.8%) and prolonged QT interval (4.5% vs. 2.1%).

RELATED REPORTS

Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer

Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer

#VisualAbstract: Fulvestrant plus cyclin-dependent kinase 4/6 inhibitors improves survival in HR⁺, HER2- metastatic breast cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced breast cancerCDK4/6 inhibitorribociclib
Previous Post

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

Next Post

Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma

RelatedReports

Oncology

Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer

March 28, 2022
Endocrinology

Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer

March 17, 2022
#VisualAbstract: Fulvestrant plus cyclin-dependent kinase 4/6 inhibitors improves survival in HR⁺, HER2- metastatic breast cancer
StudyGraphics

#VisualAbstract: Fulvestrant plus cyclin-dependent kinase 4/6 inhibitors improves survival in HR⁺, HER2- metastatic breast cancer

February 15, 2022
#VisualAbstract: Internal mammary node irradiation improves survival for patients with centromedially located node-positive breast cancer
StudyGraphics

#VisualAbstract: Internal mammary node irradiation improves survival for patients with centromedially located node-positive breast cancer

November 9, 2021
Next Post
Increased frailty associated with childhood cancer survivorship

Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma

2 Minute Rewind November 29, 2021

Multiple factors impact racial and ethnic disparities in opioid use disorder treatment during pregnancy

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.